Establishment of a method for the assessment of brain function measuring the expression level of ubiquitin ligase and its application for pharmacotherapeutics
| Project/Area Number |
25860112
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Omura Tomohiro 京都大学, 医学(系)研究科(研究院), 助教 (00439035)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 神経変性疾患 / HRD1 / SEL1L / ユビキチンリガーゼ / パーキンソン病 / 6-OHDA / 神経化学 / 小胞体ストレス |
|---|
| Outline of Final Research Achievements |
It is very useful if we can objectively assess brain function through the measurement of marker proteins. I therefore analyze the function of ubiquitin ligase HRD1 and SEL1L, a HRD1 stabilizer, related to neurodegenerative diseases using Parkinson’s disease (PD) model cells.
We confirmed that the mRNA and protein levels of HRD1 or SEL1L are upregulated in the PD model, indicating that it is possible that these molecules might be disease markers in PD. Moreover, HRD1 and SEL1L coordinated to suppress neuronal cell death in PD model, suggesting that the HRD1-SEL1L complex may potentially be one of the novel therapeutic targets in PD.
|
Report
(4 results)
Research Products
(3 results)
